Clinical Trial Update: Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1/Phase 2 safety study evaluating a CXCR4 antagonist in patients with multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CXCR4 antagonist (unnamed) (CXCR4 antagonist)

Snippet

Sponsor: Biokine Therapeutics Ltd | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED